Drug lookup | Fillwise

NEBIVOLOL HYDROCHLORIDE

All strengths: Off-Formulary Interchangeable, not an ODB benefit; same patient cost rules

Shared coverage and patient cost rules

StatusOff-Formulary Interchangeable, not an ODB benefit

Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (C07A, C07AB) — coverage varies; not interchangeable

Acebutolol (Sectral): general benefit, Not a benefit
Atenolol (Apo-Atenol): general benefit
Bisoprolol (Sandoz Bisoprolol Tablets): general benefit, Not a benefit
Metoprolol (Lopresor SR): general benefit, Not a benefit
Nadolol (Corgard): general benefit, Not a benefit
Propranolol (Inderal-LA): general benefit, Not a benefit

3 more in the class list below

Bystolic · DIN 02398990 · 2.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Savings card: RxHelp ONE lists Bystolic (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)

1 brand, same coverage

Bystolic · DIN 02398990 Manufacturer: AbbVie Corporation; listing date 2026-05-29 Health Canada: Marketed since 2024-04-19 · brand BYSTOLIC · ATC C07AB12 NEBIVOLOL · form Tablet · route Oral · ingredients NEBIVOLOL (NEBIVOLOL HYDROCHLORIDE) 2.5 MG · company Abbvie corporation · schedule Prescription

Check this DIN again · Health Canada product record

Bystolic: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88390 · Verify on the e-Formulary ↗ (DIN 02398990)

Source record

DIN 02398990: Bystolic Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240400181; group id 287; item number 0614; lccId None; manufacturer id ABV Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02398990 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88390

Interchangeable products

PRZ-Nebivolol · DIN 02548704 · not recorded

Shortage status: resolved shortage (ended 2023-11-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02398990

Shortage record checked 2026-09-13T08:10:21.292534+00:00

PRZ-Nebivolol · DIN 02548704 · 2.5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

PRZ-Nebivolol · DIN 02548704 Manufacturer: Pharmaris Canada Inc.; listing date 2026-05-29 Health Canada: Marketed since 2025-12-18 · brand PRZ-NEBIVOLOL · ATC C07AB12 NEBIVOLOL · form Tablet · route Oral · ingredients NEBIVOLOL (NEBIVOLOL HYDROCHLORIDE) 2.5 MG · company Pharmaris canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103755 · Verify on the e-Formulary ↗ (DIN 02548704)

Source record

DIN 02548704: PRZ-Nebivolol Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240400181; group id 287; item number 0614; lccId None; manufacturer id PRZ Source form: Tab; strength: 2.5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.2719; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02548704 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103755

Interchangeable products

Bystolic · DIN 02398990 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02548704

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Bystolic · DIN 02399008 · 5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Savings card: RxHelp ONE lists Bystolic (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)

1 brand, same coverage

Bystolic · DIN 02399008 Manufacturer: AbbVie Corporation; listing date 2026-05-29 Health Canada: Marketed since 2023-11-22 · brand BYSTOLIC · ATC C07AB12 NEBIVOLOL · form Tablet · route Oral · ingredients NEBIVOLOL (NEBIVOLOL HYDROCHLORIDE) 5 MG · company Abbvie corporation · schedule Prescription

Check this DIN again · Health Canada product record

Bystolic: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Source record

DIN 02399008: Bystolic Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240400182; group id 287; item number 0615; lccId None; manufacturer id ABV Source form: Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02399008 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88391

Interchangeable products

PRZ-Nebivolol · DIN 02548712 · not recorded

Shortage status: resolved shortage (ended 2025-01-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02399008

Shortage record checked 2026-09-13T08:10:21.292534+00:00

PRZ-Nebivolol · DIN 02548712 · 5mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

PRZ-Nebivolol · DIN 02548712 Manufacturer: Pharmaris Canada Inc.; listing date 2026-05-29 Health Canada: Marketed since 2025-12-18 · brand PRZ-NEBIVOLOL · ATC C07AB12 NEBIVOLOL · form Tablet · route Oral · ingredients NEBIVOLOL (NEBIVOLOL HYDROCHLORIDE) 5 MG · company Pharmaris canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103756 · Verify on the e-Formulary ↗ (DIN 02548712)

Source record

DIN 02548712: PRZ-Nebivolol Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240400182; group id 287; item number 0615; lccId None; manufacturer id PRZ Source form: Tab; strength: 5mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.7482; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02548712 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103756

Interchangeable products

Bystolic · DIN 02399008 · not recorded

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Bystolic · DIN 02399016 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Savings card: RxHelp ONE lists Bystolic (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)

1 brand, same coverage

Bystolic · DIN 02399016 Manufacturer: AbbVie Corporation; listing date 2026-05-29 Health Canada: Marketed since 2024-08-19 · brand BYSTOLIC · ATC C07AB12 NEBIVOLOL · form Tablet · route Oral · ingredients NEBIVOLOL (NEBIVOLOL HYDROCHLORIDE) 10 MG · company Abbvie corporation · schedule Prescription

Check this DIN again · Health Canada product record

Bystolic: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Source record

DIN 02399016: Bystolic Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240400183; group id 287; item number 0616; lccId None; manufacturer id ABV Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02399016 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88392

Interchangeable products

PRZ-Nebivolol · DIN 02548720 · not recorded

Shortage status: resolved shortage (ended 2023-08-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02399016

Shortage record checked 2026-09-13T08:10:21.292534+00:00

PRZ-Nebivolol · DIN 02548720 · 10mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

PRZ-Nebivolol · DIN 02548720 Manufacturer: Pharmaris Canada Inc.; listing date 2026-05-29 Health Canada: Marketed since 2025-12-18 · brand PRZ-NEBIVOLOL · ATC C07AB12 NEBIVOLOL · form Tablet · route Oral · ingredients NEBIVOLOL (NEBIVOLOL HYDROCHLORIDE) 10 MG · company Pharmaris canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103757 · Verify on the e-Formulary ↗ (DIN 02548720)

Source record

DIN 02548720: PRZ-Nebivolol Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240400183; group id 287; item number 0616; lccId None; manufacturer id PRZ Source form: Tab; strength: 10mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.2719; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02548720 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103757

Interchangeable products

Bystolic · DIN 02399016 · not recorded

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Bystolic · DIN 02399024 · 20mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Savings card: RxHelp ONE lists Bystolic (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)

1 brand, same coverage

Bystolic · DIN 02399024 Manufacturer: AbbVie Corporation; listing date 2026-05-29 Health Canada: Marketed since 2024-07-02 · brand BYSTOLIC · ATC C07AB12 NEBIVOLOL · form Tablet · route Oral · ingredients NEBIVOLOL (NEBIVOLOL HYDROCHLORIDE) 20 MG · company Abbvie corporation · schedule Prescription

Check this DIN again · Health Canada product record

Bystolic: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Source record

DIN 02399024: Bystolic Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240400184; group id 287; item number 0617; lccId None; manufacturer id ABV Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02399024 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88393

Interchangeable products

PRZ-Nebivolol · DIN 02548739 · not recorded

Shortage status: resolved shortage (ended 2022-08-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02399024

Shortage record checked 2026-09-13T08:10:21.292534+00:00

PRZ-Nebivolol · DIN 02548739 · 20mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

PRZ-Nebivolol · DIN 02548739 Manufacturer: Pharmaris Canada Inc.; listing date 2026-05-29 Health Canada: Marketed since 2025-12-19 · brand PRZ-NEBIVOLOL · ATC C07AB12 NEBIVOLOL · form Tablet · route Oral · ingredients NEBIVOLOL (NEBIVOLOL HYDROCHLORIDE) 20 MG · company Pharmaris canada inc · schedule Prescription

Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103758 · Verify on the e-Formulary ↗ (DIN 02548739)

Source record

DIN 02548739: PRZ-Nebivolol Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 240400184; group id 287; item number 0617; lccId None; manufacturer id PRZ Source form: Tab; strength: 20mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.2719; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02548739 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103758

Interchangeable products

Bystolic · DIN 02399024 · not recorded

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered

Matched class: 24:04 Cardiac Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ATENOLOL, DIGOXIN, PROPAFENONE HCL Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMIODARONE HCL, AMLODIPINE, BISOPROLOL FUMARATE, DILTIAZEM HCL, DISOPYRAMIDE, FLECAINIDE ACETATE, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, NIFEDIPINE, PROPRANOLOL, SOTALOL HCL, TIMOLOL MALEATE, VERAPAMIL HCL 24:00 CARDIOVASCULAR DRUGS

RANOLAZINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:04 Cardiac Drugs

ACEBUTOLOL HCL

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 100mg, 200mg, 400mg · Tab

ATENOLOL

· 26 products · General benefit · strengths: 50mg, 100mg · Tab

BISOPROLOL FUMARATE

· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab

METOPROLOL TARTRATE

· 28 products · Listed, not a benefit (6), General benefit (22) · strengths: 100mg, 200mg, 50mg · LA Tab, Tab

NADOLOL

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 40mg, 80mg, 160mg · Tab

PROPRANOLOL

· 19 products · Off-Formulary Interchangeable, not an ODB benefit (8), General benefit (7), Listed, not a benefit (4) · strengths: 60mg, 80mg, 120mg, 160mg, 10mg, 20mg, 40mg · LA Cap, Tab

SOTALOL HCL

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 80mg, 160mg · Tab

TIMOLOL MALEATE

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CARVEDILOL

· 36 products · Listed, not a benefit (4), Limited Use, codes 183 (32) · strengths: 3.125mg, 6.25mg, 12.5mg, 25mg · Tab

AMIODARONE HCL

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 200mg · Tab

AMLODIPINE

· 56 products · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) · strengths: 1mg/mL, 2.5mg, 5mg, 10mg · Oral Sol, Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:04 and 9 more

Full class listing Related classes: 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.

Other drugs whose Health Canada label lists a similar indication: hypertension

From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE ACEBUTOLOL HCL · Listed, not a benefit (3), General benefit (6) INDICATIONS AND CLINICAL USE APO-ACEBUTOLOL is indicated for the following:  Treatment of mild to moderate hypertension.  Long-term management of patients with angina pectoris due to ischemic heart disease. PM: https://pdf.hres.ca/dpd_pm/00047998.PDF; date October 24, 2018; DIN 02147602; fetched 2026-09-10 Product monograph AMLODIPINE · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) 1 INDICATIONS NORVASC (amlodipine besylate tablets) is indicated for: • Hypertension NORVASC is indicated in the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00071908.PDF; date AUG 02, 2023; DIN 00878928; fetched 2026-09-10 Product monograph AZILSARTAN MEDOXOMIL · Off-Formulary Interchangeable, not an ODB benefit 1 Part 1: Healthcare Professional Information Indications • EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) indicated for the treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00082489.PDF; date 2025-10-24; DIN 02381389; fetched 2026-09-10 Product monograph BENAZEPRIL · Listed, not a benefit (3), General benefit (3) Indications BENAZEPRIL (benazepril hydrochloride tablets) is indicated for:  Treatment of mild to moderate essential hypertension. PM: https://pdf.hres.ca/dpd_pm/00080887.PDF; date 2025-06-24; DIN 02273918; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL · General benefit • Heart Failure o The treatment of NYHA Class II and III heart failure with ejection fraction ≤ 40% in addition to standard therapy, with or without an ACE inhibitor. 1.1 Pediatrics Pediatrics (6 to 17 years of age): • Hypertension ATACAND is indicated for the treatment of essential hypertension in children and adolescents 6 to 17 years of age (see 7.1.3 Pediatrics, 14 CLINICAL TRIALS). PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph • Hypertension PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10 Product monograph CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS ATACAND PLUS (candesartan cilexetil/hydrochlorothiazide) is indicated for: • the treatment of essential hypertension in patients for whom combination therapy is appropriate. PM: https://pdf.hres.ca/dpd_pm/00076288.PDF; date JUN 18, 2001; DIN 02244021; fetched 2026-09-10 Product monograph CHLORTHALIDONE · Listed, not a benefit (1), General benefit (2) 1 INDICATIONS APO-CHLORTHALIDONE (chlorthalidone) is indicated for: • Treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00069909.PDF; date MAR 14, 2023; DIN 00360279; fetched 2026-09-10 Product monograph CILAZAPRIL & HYDROCHLOROTHIAZIDE · General benefit 1 INDICATIONS INHIBACE PLUS (cilazapril and hydrochlorothiazide) is indicated for:  treatment of mild to moderate essential hypertension in patients for whom combination therapy with both cilazapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00066994.PDF; date September 07, 1995; DIN 02181479; fetched 2026-09-10 Product monograph CLONIDINE HCL · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) INDICATIONS AND CLINICAL USE TEVA-CLONIDINE (clonidine hydrochloride) is indicated for the treatment of hypertension. PM: https://pdf.hres.ca/dpd_pm/00024986.PDF; date April 25, 2014; DIN 02046121; fetched 2026-09-10 Product monograph ENALAPRIL MALEATE & HYDROCHLOROTHIAZIDE · Off-Formulary Interchangeable, not an ODB benefit 1 INDICATIONS VASERETIC® (enalapril and hydrochlorothiazide) is indicated for:  Treatment of essential hypertension in patients for whom this combination therapy with enalapril and hydrochlorothiazide is appropriate. PM: https://pdf.hres.ca/dpd_pm/00068096.PDF; date November 4, 2022; DIN 00657298; fetched 2026-09-10 Product monograph and 20 more Coverage source: ON formulary extract 2026-08-26

What the Health Canada label says it is for

1 INDICATIONS BYSTOLIC® (nebivolol tablets) is indicated for:  The treatment of mild to moderate essential hypertension. BYSTOLIC may be used alone or concomitantly with thiazide diuretics or angiotensin converting enzyme (ACE) inhibitors. See 9 DRUG INTERACTIONS, 4.2 Recommended Dose and Dosage Adjustment and 14 CLINICAL TRIALS. BYSTOLIC is not recommended for the emergency treatment of hypertensive crises. 1.1 Pediatrics The safety and efficacy of BYSTOLIC in pediatric patients have not been established and therefore use in children is not recommended. 1.2 Geriatrics No dosage adjustment is required in geriatric patients. Of the total number of patients receiving BYSTOLIC in clinical studies, 436 (18%) were 65 years of age or older. No differences in efficacy or safety of BYSTOLIC were observed between older and younger patients. See 4.2 Recommended Dose and Dosage Adjustment and 10.3 Pharmacokinetics. https://pdf.hres.ca/dpd_pm/00068128.PDF PM date: December 19, 2012 Source product: BYSTOLIC; DIN 02398990; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Bystolic, PRZ-Nebivolol: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote

Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote

Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026